Table of Contents
Friday, 03 May 2013
Welcome
13.10 - 13.30
Setting the Scene: Current Status of Surgical
and Medical mRCC-Treatment
Ronald M. Bukowski, M.D.
Pathology and Prognosis
13.30 - 13.45
Pathology of RCC: What do Clinicians
Need to Know
Holger Moch, M.D.
13.45 - 14.00
Rare Metastatic Sites in mRCC: A Different Disease?
Gerald Mickisch, M.D.
14.00 - 14.15
Depressive Symptoms as Key Predictors of Survival in mRCC
Eric Jonasch, M.D.
14.15 - 14.30
What Should we Do About Patients with Brain Metastases?
Vincent Khoo, M.D.
Surgical Aspects of mRCC Treatment
15.10 - 15.20
Debate: Lymphadenectomy is Important in mRCC PRO
Christopher G. Wood, M.D., FACS
15.20 - 15.30
Debate: Lymphadenectomy is Important in mRCC CON
Jean Jacques Patard, M.D.
15.30 - 15.40
Small Primary in Metastatic Disease: Is it Worth to be Removed? PRO
Gerald Mickisch, M.D.
15.40 - 15.50
Small Primary in Metastatic Disease: Is it Worth to be Removed? CON
Jean Jacques Patard, M.D.
15.50 - 16.00
Surgical Treatment of Atypical Metastases from RCC
Nicola Arrighi, M.D.
16.00 - 16.15
What Does the Medical Oncologist Expect from the Surgeon Including Case (and
Metastasectomy)
Manuela Schmidinger, M.D.
16.15 - 16.45
Cases Presentation
Professor Peter Tenke, M.D.
Csaba Pustzai, M.D., Ph.D.
Arnaud Méjean, M.D., Ph.D.
Saturday, 04 May 2013
Systemic mRCC Treatment (after COMPARZ, PISCES, BevLin and TORAVA...)
08.05 - 08.15
Pazopanib is the Best Choice in First-Line
Fabio Calabro, M.D.
08.15 - 08.25
Sunitinib Remains the Best Choice in First-Line
Camillo Porta, M.D.
08.25 - 08.35
Bevacizumab+Low Dose IFN is the Best Choice in First-Line
Bohuslav Melichar, M.D.
08.35 - 08.45
Will Highly Selective TKIs Become First-Line Standard of Care?
Joaquim Bellmunt, M.D.
08.45 - 09.00
Second-Line Strategies
Viktor Grünwald, M.D.
09.00 - 09.25
Case 1: Success in mRCC (with an Unusual Strategy)
Sylvie Negrier, M.D., Ph.D.
Case 2: Success in mRCC
Rosalie Fisher, M.D.
The Role of Additional Strategies in mRCC
09.50 - 10.00
The Cytokine-Era is Over: What Should We Do About Sorafenib?
James Larkin, Ph.D., MRCP
10.00 - 10.10
EGFR-Targeting in mRCC: A Closed Chapter?
Alain Ravaud, M.D., Ph.D.
10.10 - 10.20
Are Currently Available mTOR-Inhibitors Convincing in mRCC?
Tim Eisen, M.D.
10.20 - 10.30
Novel Immunotherapeutic Approaches in mRCC
David F. McDermott, M.D.
Many Open Questions in RCC
10.40 - 10.50
10.50 - 11.00
Management of Papillary Type 2 mRCC and Case and Study
Thomas Powles, M.D., MBBS, MRCP
11.00 - 11.10
Management of Translocational Tumors and Case and Study
Cora N. Sternberg, M.D., FACP
11.10 - 11.20
Management of Collecting Duct Carcinoma and Case
Emiliano Calvo, M.D., Ph.D.
11.20 - 11.30
Strategies Beyond VEGF-Inhibitors and mTOR-Inhibitors
Bernard Escudier, M.D.
11.30 - 11.40
Case(s): How to Deal with Mixed Response
Giuseppe Procopio, M.D.
11.55 - 12.30
Challenges From Treatment and From the Disease
14.15 - 14.30
Rare Complications of Systemic mRCC Treatment
Sergio Bracarda, M.D.
14.30 - 14.45
Inflammation in mRCC: Target or Prognostic Factor?
Benoit Beuselinck, M.D.
14.45 - 15.00
Management of Chronic Renal Failure Under Anti-VEGF-Directed Treatment
Christian Kollmannsberger, M.D.
15.00 - 15.15
Metabolic Disorders
Paul Nathan, FRCP, Ph.D.
15.15 - 15.30
Mechanisms and Management of Diarrhea from Anti-VEGFR-TKIs
Manuela Schmidinger, M.D.
Long-Term Survival in mRCC
16.10 - 16.20
Complete Remission is a Reachable Goal in mRCC
Laurence Albiges, M.D.
16.20 - 16.30
mRCC-Favorable Risk Long-Term Survivor: Case 1
Cesary Szczylik, M.D.
16.30 - 16.40
mRCC Intermediate Risk Long-Term Survivor: Case 2
Sylvie Negrier, M.D., Ph.D.
16.40 - 16.50
mRCC Poor Risk Long-Term Survivor: Case 3
Rosalie Fisher, M.D.